GMAB News and Press, Genmab A/S From 05/09/20

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Image source: The Motley Fool. Genmab A/S   (NASDAQ: GMAB) Q1 2020 Earnings Call May 6, 2020 , 12:00 p.m. ET Operator Continue reading

The following slide deck was published by Genmab A/S in conjunction with their 2020 Q1 earnings Read more ...

Genmab (NASDAQ: GMAB ): Q1 GAAP EPS of DKK4.09. More news on: Genmab A/S, Genmab A/S, Earnings news and commentary, Tech stocks news, Read more ...

The FDA approves a subcutaneous formulation of Johnson & Johnson's ( JNJ -1.9% ) multiple myeloma med Darzalex (daratumumab). Originally, the CD38-directed cytolytic antibody was administered via intravenous infusion. More news on: Johnson & Johnson, Halozyme Therapeutics, Inc....

The European Medicines Agency's advisory group CHMP has adopted a positive opinion backing approval of a subcutaneous formulation of Johnson & Johnson's ( JNJ -0.6% ) multiple myeloma med Darzalex (daratumumab). More news on: Johnson & Johnson, Genmab A/S, Healthcare stocks new...

Intro & pipeline Agenus ( AGEN ) is an immuno-oncology ((IO)) company with a deep and diversified pipeline, a technology for novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing. Agenus believes that the...

Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for On-Demand Viewing Canada NewsWire NEW YORK, March 26, 2020 NEW YORK , March 26, 2020 /CNW/ - Deutsche Bank today announced that the presentations from the March 18 th and 19...

NEW YORK , March 26, 2020 /PRNewswire/ -- Deutsche Bank today announced that the presentations from the March 18 th and 19 th Depositary Receipts Virtual Investor Conference ("dbVIC") are now available for on-demand viewing. The event featured presentations from international companie...

Today, we will see why Genmab (GMAB) is an attractive biotech pick in March 2020. Company overview Genmab is a dual-listed biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. The company was founded in 19...